Want to see MRNA full AI Analyst Report?
MRNA Stock Chart & Stats
$158.83
-$2.95(-5.17%)
At close: 4:00 PM EDT
$158.83
-$2.95(-5.17%)
Day’s Range― - ―
52-Week Range$22.28 - $187.20
Previous CloseN/A
Volume4.43M
Average Volume (3M)25.95M
Market Cap
$69.04B
Enterprise Value$24.02K
Total Cash (Recent Filing)$5.14B
Total Debt (Recent Filing)$1.29B
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Oct 29, 2026EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.98
Shares Outstanding399,235,900
10 Day Avg. Volume10,981,966
30 Day Avg. Volume25,947,088
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$107.29Price Target Upside-32.45% Downside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)-8.31
Revenue Forecast (FY)$2.10B
Bulls Say, Bears Say
Bulls Say
Respiratory Portfolio ExpansionRegulatory approvals and procurement commitments broaden Moderna’s respiratory franchise beyond COVID-19 and create additional commercial channels. Geographic expansion can support more diversified vaccine revenue over the next several quarters, although uptake will depend on launches and market adoption.
MNEXSPIKE Market Position And EffectivenessStrong uptake among the important older-adult segment, combined with reported real-world effectiveness, supports product competitiveness and physician or customer confidence. This gives Moderna a durable commercial base while newer respiratory products are being launched and evaluated.
Financial FlexibilityManageable leverage and substantial liquidity provide room to fund research, launches, and operating needs while revenue recovers. Although cash is declining, the balance sheet gives Moderna greater strategic flexibility than a highly indebted biotechnology company facing similar losses.
Bears Say
Deeply Negative ProfitabilityPersistent negative margins show that the current revenue base is not covering Moderna’s operating cost structure. Without a durable improvement in product sales or major cost absorption, continued losses could pressure equity, restrict investment capacity, and weaken long-term earnings quality.
Persistent Cash BurnNegative operating and free cash flow means Moderna is not currently self-funding its business and pipeline. Ongoing cash outflows can reduce the resources available for development and commercialization, making future progress increasingly dependent on existing liquidity or external financing.
COVID Exposure And Pipeline Timing RiskThe transition away from COVID-driven demand remains a structural revenue challenge because replacement products are not yet contributing under current guidance. Delayed or unsuccessful pipeline programs could extend concentration in a declining market and postpone meaningful diversification.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $187.20 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $69.04B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 29, 2026 which is in 36 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Jul 31, 2026. The company reported -$1.97 earnings per share for the quarter, beating the consensus estimate of -$2.032 by $0.062.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -1.1.
How many shares outstanding does Moderna have?
Moderna has 399,235,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$1.97 in its last earnings report, beating expectations of -$2.032. Following the earnings report the stock price went down -5.352%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$107.29 (-32.45% Downside)
$107.29 (-32.45% Downside)
Blogger Sentiment
Neutral
MRNA Sentiment 56%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 50.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
587.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial and clinical progress — a Q2 revenue beat, multiple regulatory and market milestones (including a VRBPAC recommendation for the flu candidate and expanded approvals for respiratory products), clear cost and efficiency improvements, and advancing oncology/rare disease programs with important data and new dosing initiatives. These positives were tempered by a norovirus Phase III interim that did not meet early success criteria and slower case accrual, a significant litigation settlement payment (~$950M) that reduced cash, a substantial net loss and continued cash burn, and timing uncertainty for several event‑driven readouts. On balance, the highlights (regulatory momentum, product approvals/market uptake, cost discipline and pipeline advances) modestly outweigh the lowlights, supporting a constructive but cautious outlook.View all MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$107.29
▼(-32.45% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.78% Insiders
28.04% Mutual Funds
19.17% Other Institutional Investors
21.39% Public Companies and Individual Investors